From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions.

ABSTRACT: Anticancer nanomedicines have been studied over 30 years, but fewer than 10 formulations have been approved for clinical therapy today. Despite abundant options of anticancer drugs, it remains challenging to have agents specifically target cancer cells while reducing collateral toxicity to healthy tissue. Nanocompartments that can be selective toward points deeply within malignant tissues are a promising concept, but the heterogeneity of tumor tissue, inefficiency of cargo loading and releasing, and low uniformity of manufacture required from preclinical to commercialization are major obstacles. Technological advances have been made in this field, creating engineered nanomaterials with improved uniformity, flexibility of cargo loading, diversity of surface modification, and less inducible

SUBMITTER: Chiang CL 

PROVIDER: S-EPMC8308137 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature